000			02329na a2200241 4500
003			H12O
005			20180417112253.0
008			130622s2011 xxx||||| |||| 00| 0 eng d
040			_cH12O
041			_aeng
100			_aCortés-Funes Castro, Hernán _91181 _eOncología Médica
100			_aGhanem Cañete, Ismael _91793 _eOncología Médica
245	0	0	_aSafety and efficacy of moderate-dose capecitabine as first-line therapy in metastatic breast cancer _h[artículo]
260			_bExpert Review of Anticancer Therapy, _c2011
300			_a11(2):165-168.
500			_aFormato Vancouver: Cortes-Funes H, Ghanem I. Safety and efficacy of moderate-dose capecitabine as first-line therapy in metastatic breast cancer. Expert Rev Anticancer Ther. 2011 Feb;11(2):165-8.
501			_aPMID: 21342034
504			_aContiene 20 referencias
520			_aEvaluation of: Kaufmann M, Maass N, Costa SD et al. First-line therapy with moderate dose capecitabine in metastatic breast cancer is safe and active: results of the MONICA trial. Eur. J. Cancer 46, 3184-3191 (2010). Breast cancer is the most frequent malignant disease in women. Although fewer than 10% of patients show metastatic disease at diagnosis, approximately one in every five patients will relapse. Great biologic heterogeneity in breast cancer is well known due to the implementation of newer molecular technologies. This knowledge has led to a better development and selection of new therapies. Regimens based on taxanes and anthracyclines are the classical treatments accepted as first-line therapy. Capecitabine is an orally administered systemic prodrug of 5´-deoxy-5-fluorouridine, which is converted to 5-fluorouracil with a favorable but different toxicity profile to other cytotoxic drugs. However, a considerable proportion of patients need to suspend or reduce the dose of capecitabine when it is administrated at the registered dose of 1250 mg/m(2) twice daily 14 days every 21 owing to adverse events. In this study, Kaufmann et al. show the activity and safety of capecitabina at a lower dose (1000 mg/m(2) twice daily) at first-line therapy in HER2-negative metastatic breast cancer.
710			_9303 _aServicio de Oncología Médica
856			_uhttp://pc-h12o-es.m-hdoct.a17.csinet.es/pdf/pc/3/pc3105.pdf _ySolicitar documento
942			_n0 _2ddc _cART
999			_c3105 _d3105